Menopause: Developing a rational treatment plan

References

• Barnabei V M, et al. Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstet Gynecol 2002; 100(6)1209–1218
   Google Scholar
• Greendale G A, et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol 1998; 92(6)982–988
   PubMed Web of Science ®Google Scholar
• Keating N L, et al. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 1999; 130(7)545–553
   Google Scholar
• Hersh A, Stefanick M, Stafford R. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004; 291(1)47–53
   PubMed Web of Science ®Google Scholar
• CDC. Incidence and costs to Medicare of fractures among Medicare beneficiaries aged > 65 years – United States (July 1991–June 1992). MMWR 1996; 45: 877–883
   Google Scholar
• Rossouw J E. Hormones, genetic factors, and gender differences in cardiovascular disease. Cardiovasc Res 2002; 53(3)550–557
   PubMed Web of Science ®Google Scholar
• PEPI. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995; 273(3)199–208
   Google Scholar
• Hulley S, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280(7)605–613
   PubMed Web of Science ®Google Scholar
• Cherry N, et al. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 2002; 360(9350)2001–2008
   PubMed Web of Science ®Google Scholar
• Writing Group for the Women's Health Initiative Investigators. Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002; 288: 321–333
   PubMed Web of Science ®Google Scholar
• Hsia J, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006; 166(3)357–365
   Google Scholar
• Herrington D M, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343(8)522–529
   PubMed Web of Science ®Google Scholar
• Waters D D, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002; 288(19)2432–2440
   PubMed Web of Science ®Google Scholar
• Hodis H N, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 2003; 349(6)535–545
   PubMed Web of Science ®Google Scholar
• Hodis H N, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 135(11)939–953
   PubMed Web of Science ®Google Scholar
• Harman S, Brinton E, Cedars M, Lobo R, Manson J, Merriam G, Miller V, Naftolin F, Santoro N. KEEPS: The Kronos Early Estrogen Prevention Study. Climateric 2005; 8(1)3–12
   PubMed Web of Science ®Google Scholar
• Evangelopoulos D, et al. Molecular analysis of the estrogen receptor alpha gene in men with coronary artery disease: association with disease status. Clin Chim Acta 2003; 331(1–2)37–44
   Google Scholar
• Kunnas T A, et al. Association of polymorphism of human alpha oestrogen receptor gene with coronary artery disease in men: a necropsy study. BMJ 2000; 321(7256)273–274
   Google Scholar
• Lehtimaki T, et al. Coronary artery wall atherosclerosis in relation to the estrogen receptor 1 gene polymorphism: an autopsy study. J Mol Med 2002; 80(3)176–180
   Google Scholar
• Matsubara Y, et al. Genotype distribution of estrogen receptor polymorphisms in men and postmenopausal women from healthy and coronary populations and its relation to serum lipid levels. Arterioscler Thromb Vasc Biol 1997; 17(11)3006–3012
   Google Scholar
• Petrovic D, Peterlin B. Estrogen receptor dinucleotide (TA) polymorphism does not predict premature myocardial infarction in Caucasian women. Cardiology 2003; 99(3)163–165
   Google Scholar
• Shearman A M, et al. Association between estrogen receptor alpha gene variation and cardiovascular disease. JAMA 2003; 290(17)2263–2270
   PubMed Web of Science ®Google Scholar
• Moniek P, deMaat M, Madsen J, Langdahl B, Bladbjerg E, Tofteng C, Abrahamsen B, Rejnmark L, Brixen K, Christensen K, Jespersen J, Kristensen S. Genetic variation in estrogen receptor, C-reactive protein and fibrinogen does not predict the plasma levels of inflammatory markers after longterm hormone replacement therapy. Thrombosis and Haemostasis 2007; 97(2)234–239
   Google Scholar
• Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, Virkamaki A, Hovatta O, Hamsten A, Taskinen M R, Yki-Jarvinen H. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal woman. Thrombosis and Haemostasis 2001; 85(4)619–625
   Google Scholar
• Koh K K, et al. Relation of fibrinolytic potentiation by estrogen to coagulation pathway activation in postmenopausal women. Am J Cardiol 1999; 83(3)466–469, A10
   Google Scholar
• Manson J E, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349(6)523–534
   PubMed Web of Science ®Google Scholar
• Psaty B M, et al. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA 2001; 285(7)906–913
   Google Scholar
• Shlipak M G, et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 2000; 283(14)1845–1852
   PubMed Web of Science ®Google Scholar
• Gebara O C, et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995; 91(7)1952–1958
   Google Scholar
• Baker L, et al. The role of estrogen in cardiovascular disease. J Surg Res 2003; 115(2)325–344
   PubMed Web of Science ®Google Scholar
• Oian P, Osterud B. Monocyte-platelet function and protection against cardiovascular disease. Maturitas 1996; 23(Suppl)S57–S60
   Google Scholar
• Nelson H D, et al. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002; 288(7)872–881
   PubMed Web of Science ®Google Scholar
• Daling J R, et al. Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer 2002; 95(12)2455–2464
   Google Scholar
• Daling J R, et al. Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50–64 years. Cancer Epidemiol Biomarkers Prev 2003; 12(11 Pt 1)1175–1181
   Google Scholar
• Li C I, et al. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer 2000; 88(11)2570–2577
   Google Scholar
• Newcomer L M, et al. Postmenopausal hormone therapy and risk of breast cancer by histologic type (United States). Cancer Causes Control 2003; 14(3)225–233
   Google Scholar
• Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001; 344(4)276–285
   PubMed Web of Science ®Google Scholar
• Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362(9382)419–427
   PubMed Web of Science ®Google Scholar
• Stefanick M L, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006; 295(14)1647–1657
   PubMed Web of Science ®Google Scholar
• Li C I, Moe R E, Daling J R. Risk of mortality by histologic type of breast cancer among women aged 50 to 79 years. Arch Intern Med 2003; 163(18)2149–2153
   Google Scholar
• Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer – is it safe?), a randomised comparison: trial stopped. Lancet 2004; 363(9407)453–455
   PubMed Web of Science ®Google Scholar
• Sellers T A, et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 1997; 127(11)973–980
   PubMed Web of Science ®Google Scholar
• Cauley J A, et al. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1995; 122(1)9–16
   PubMed Web of Science ®Google Scholar
• Maxim P, Ettinger B, Spitalny G M. Fracture protection provided by long-term estrogen treatment. Osteoporos Int 1995; 5(1)23–29
   PubMed Web of Science ®Google Scholar
• Torgerson D J, Bell-Syer S E. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001; 285(22)2891–2897
   PubMed Web of Science ®Google Scholar
• Ralston S H. Genetic determinants of susceptibility to osteoporosis. Curr Opin Pharmacol 2003; 3(3)286–290
   Google Scholar
• Morrison N A, et al. Prediction of bone density from vitamin D receptor alleles. Nature 1994; 367(6460)284–287
   PubMed Web of Science ®Google Scholar
• Cooper G S, Umbach D M. Are vitamin D receptor polymorphisms associated with bone mineral density? A meta-analysis. J Bone Miner Res 1996; 11(12)1841–1849
   Google Scholar
• Graafmans W C, et al. The effect of vitamin D supplementation on the bone mineral density of the femoral neck is associated with vitamin D receptor genotype. J Bone Miner Res 1997; 12(8)1241–1245
   Google Scholar
• Garcia-Giralt N, et al. Two new single-nucleotide polymorphisms in the COL1A1 upstream regulatory region and their relationship to bone mineral density. J Bone Miner Res 2002; 17(3)384–393
   Google Scholar
• Weel A E, et al. Estrogen receptor polymorphism predicts the onset of natural and surgical menopause. J Clin Endocrinol Metab 1999; 84(9)3146–3150
   PubMed Web of Science ®Google Scholar
• Sherwin B B. Estrogen and cognitive functioning in women. Endocr Rev 2003; 24(2)133–151
   PubMed Web of Science ®Google Scholar
• McEwen B. Estrogen actions throughout the brain. Recent Prog Horm Res 2002; 57: 357–384
   PubMedGoogle Scholar
• Luine V N. Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Exp Neurol 1985; 89(2)484–490
   Google Scholar
• Yaffe K, et al. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 1998; 279(9)688–695
   PubMed Web of Science ®Google Scholar
• Henderson V W, et al. Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol 1994; 51(9)896–900
   Google Scholar
• Tang M X, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996; 348(9025)429–432
   PubMed Web of Science ®Google Scholar
• Grady C L, Craik F I. Changes in memory processing with age. Curr Opin Neurobiol 2000; 10(2)224–231
   PubMed Web of Science ®Google Scholar
• Matthews K, et al. Estrogen replacement therapy and cognitive decline in older community women. J Am Geriatr Soc 1999; 47(5)518–523
   PubMed Web of Science ®Google Scholar
• Shumaker S A, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289(20)2651–2662
   PubMed Web of Science ®Google Scholar
• Shumaker S A, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004; 291(24)2947–2958
   PubMed Web of Science ®Google Scholar
• Hardy J, Selkoe D J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297(5580)353–356
   PubMed Web of Science ®Google Scholar
• Turner R S. Biomarkers of Alzheimer's disease and mild cognitive impairment: are we there yet?. Exp Neurol 2003; 183(1)7–10
   Google Scholar
• Richette P, Corvol M, Bardin T. Estrogens, cartilage, and osteoarthritis. Joint Bone Spine 2003; 70(4)257–262
   PubMed Web of Science ®Google Scholar
• Mascarenhas P, et al. Influence of sex hormones on the periodontium. J Clin Periodontol 2003; 30(8)671–681
   PubMed Web of Science ®Google Scholar
• Paganini-Hill A. The benefits of estrogen replacement therapy on oral health. The Leisure World cohort. Arch Intern Med 1995; 155(21)2325–2329
   Google Scholar
• Sumino H, Ichikawa S, Abe M, Endo Y, Ishikawa O, Kurabayashi M. Effects of aging, menopause, and hormone replacement therapy on forearm skin elasticity in women. J Am Geriatr Soc 2004; 52(6)945–949
   PubMed Web of Science ®Google Scholar
• Ashcroft G S, Ashworth J J. Potential role of estrogens in wound healing. Am J Clin Dermatol 2003; 4(11)737–743
   PubMed Web of Science ®Google Scholar
• Camp R L, Chung G G, Rimm D L. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002; 8(11)1323–1327
   PubMed Web of Science ®Google Scholar
• Petricoin E F, et al. Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov 2002; 1(9)683–695
   PubMed Web of Science ®Google Scholar
• Schneider H P. The quality of life in the post-menopausal woman. Best Pract Res Clin Obstet Gynaecol 2002; 16(3)395–409
   Google Scholar
• Bravata D M, Rastegar A, Horwitz R I. How do women make decisions about hormone replacement therapy?. Am J Med 2002; 113(1)22–29
   Google Scholar
• Fisher W A, et al. Canadian menopause study-I: Understanding women's intentions to utilise hormone replacement therapy. Maturitas 2000; 37(1)1–14
   PubMed Web of Science ®Google Scholar
• O'Connor A M, et al. Randomized trial of a portable, self-administered decision aid for postmenopausal women considering long-term preventive hormone therapy. Med Decis Making 1998; 18(3)295–303
   PubMed Web of Science ®Google Scholar
• Woods N F, et al. Deciding about hormone therapy: validation of a model. Menopause 1998; 5(1)52–59
   Google Scholar
• Zubialde J P, Lawler F, Clemenson N. Estimated gains in life expectancy with use of postmenopausal estrogen therapy: a decision analysis. J Fam Pract 1993; 36(3)271–280
   Google Scholar
• Schapira M M, et al. Menopausal hormone therapy decisions: insights from a multi-attribute model. Patient Educ Couns 2004; 52(1)89–95
   Google Scholar